A Gaithersburg company agreed to collaborate with a startup company to develop 3D bioprinted tissues that will enable drug companies to develop and test new drugs. Medimmune, the biologics research and development arm of AstraZeneca, agreed to partner with Cellink, a 3D bioprinting company, starting in January. They bring with them Cellink’s 3D bioprinting technology. The goal is to speed up research and development of new therapies that are specific to individual patients who suffer with oncologic, respiratory, cardiovascular, renal and metabolic diseases. “This collaboration would further open the pharmaceutical development segment for Cellink and lay the groundwork for future drug-development processes,” said Gatenholm. “We’re looking forward to utilizing not only Cellink’s innovative technology, but also their direct expertise in our labs. From biotech to hi-tech, collaboration is core to how we operate and to opening new doors for the potential discovery of new therapies,” Wu said. He said, 3D printing could be perfected to implant pieces of bone or a new kidney into a patient, he said.

Read the full article at The Montgomery County Sentinel